Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;7(9):1858–1870. doi: 10.1182/bloodadvances.2022008806

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 7. — Association of RARA overexpression with monocytic features (MES) and venetoclax resistance markers in the SY-1425-201 clinical study ND unfit patients with AML. The MES and venetoclax resistance–associated features were profiled in ND unfit patients with AML. RARA-positive patients (red) were significantly enriched for features associated with venetoclax resistance including a high MES (left, y-axis), and low BCL2 (middle, y-axis) and high MCL1 expression (exp) (right, y-axis) compared with RARA-negative patients (blue). (A) Eighty percent (15/19) of RARA-positive patients and 17% (4/24) of RARA-negative patients are classified as monocytic by MES (MES > 0.5). (B) The majority of RARA-positive ND unfit patients with AML who achieved CR/CRi with tamibarotene plus azacitidine have a monocytic phenotype (high MES) associated with venetoclax resistance, which includes lower BCL2 and higher MCL1 expression.